Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis

In a retrospective study, we assessed the routine use of first-line sunitinib in 185 elderly patients with metastatic renal cell cancer (mRCC). There were no substantial differences in outcome between the standard and adapted sunitinib regimens, but the adapted was better tolerated. A sunitinib adapted regimen (AR) could be considered as an option in selected older patients.